JAZZ Insider Trading Activity and SEC Form 4 Filings
JAZZ insider trading summary
Over the past 12 months, insiders at Jazz Pharmaceuticals plc (JAZZ) reported 60 sales worth $69.3M by 10 insiders and no open-market purchases on SEC Form 4. Net insider selling was $69.3M.
Latest JAZZ insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Patricia Carr | SVP, Chief Accounting Officer | Sell | $38K (163 @ $231.27) |
| Nov 4, 2026 | Patricia Carr | SVP, Chief Accounting Officer | Sell | $289K (1,250 @ $231.37) |
| Nov 3, 2026 | Renee D Gala | President & CEO | Sell | $225K (1,000 @ $225.37) |
| Nov 2, 2026 | Bruce C Cozadd | Director | Sell | $1.3M (6,000 @ $215.84) |
| Oct 6, 2026 | Renee D Gala | President & CEO | Sell | $473K (2,000 @ $236.40) |
| Oct 1, 2026 | Bruce C Cozadd | Director | Sell | $1.4M (6,000 @ $230.33) |
| Sep 10, 2026 | Neena M Patil | EVP & Chief Legal Officer | Sell | $289K (1,200 @ $240.94) |
| Sep 1, 2026 | Bruce C Cozadd | Director | Sell | $1.5M (6,000 @ $250.13) |
| Aug 27, 2026 | Robert Iannone | EVP, Global Head of R&D & CMO | Sell | $4.5M (18,187 @ $247.86) |
| Aug 27, 2026 | Robert Iannone | EVP, Global Head of R&D & CMO | Sell | $4.5M (18,113 @ $250.02) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.